Roche Investors Might Shrug Off Results to Focus on New Cancer Drug

Dow Jones07-15

0733 GMT - Roche Holding's first-half results should contain few surprises and investors might focus instead on the upcoming launch of a new breast-cancer drug, Citi analysts say in a note. The Swiss drugmaker is expected to report steady growth in first-half sales and core earnings when it releases results next week, the analysts say. Citi estimates Roche's half-year core earnings per share at 10.36 Swiss francs on sales of 30.3 billion francs. With no binary late-stage study results left this year, investors will increasingly focus on the huge opportunity for Roche's giredestrant treatment for breast cancer, the analysts say. U.S. drug regulators are due to decide on its approval by the end of November and Citi estimates giredestrant could generate $14.5 billion in peak sales. Roche shares fall 0.4%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 15, 2026 03:33 ET (07:33 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651031430?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 15:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651031430","market":"other","top_or_hot":-1,"title":"Roche Investors Might Shrug Off Results to Focus on New Cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0733 GMT - Roche Holding's first-half results should contain few surprises and investors might focus instead on the upcoming launch of a new breast-cancer drug, Citi analysts say in a note. The Swiss drugmaker is expected to report steady growth in first-half sales and core earnings when it releases results next week, the analysts say. Citi estimates Roche's half-year core earnings per share at 10.36 Swiss francs on sales of 30.3 billion francs. With no binary late-stage study results left this year, investors will increasingly focus on the huge opportunity for Roche's giredestrant treatment for breast cancer, the analysts say. U.S. drug regulators are due to decide on its approval by the end of November and Citi estimates giredestrant could generate $14.5 billion in peak sales. Roche shares fall 0.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 15, 2026 03:33 ET (07:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Investors Might Shrug Off Results to Focus on New Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Investors Might Shrug Off Results to Focus on New Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-15 15:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0733 GMT - Roche Holding's first-half results should contain few surprises and investors might focus instead on the upcoming launch of a new breast-cancer drug, Citi analysts say in a note. The Swiss drugmaker is expected to report steady growth in first-half sales and core earnings when it releases results next week, the analysts say. Citi estimates Roche's half-year core earnings per share at 10.36 Swiss francs on sales of 30.3 billion francs. With no binary late-stage study results left this year, investors will increasingly focus on the huge opportunity for Roche's giredestrant treatment for breast cancer, the analysts say. U.S. drug regulators are due to decide on its approval by the end of November and Citi estimates giredestrant could generate $14.5 billion in peak sales. Roche shares fall 0.4%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 15, 2026 03:33 ET (07:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651031430","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651031430","pubTimestamp":1784100780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0733 GMT - Roche Holding's first-half results should contain few surprises and investors might focus instead on the upcoming launch of a new breast-cancer drug, Citi analysts say in a note. The Swiss drugmaker is expected to report steady growth in first-half sales and core earnings when it releases results next week, the analysts say. Citi estimates Roche's half-year core earnings per share at 10.36 Swiss francs on sales of 30.3 billion francs. With no binary late-stage study results left this year, investors will increasingly focus on the huge opportunity for Roche's giredestrant treatment for breast cancer, the analysts say. U.S. drug regulators are due to decide on its approval by the end of November and Citi estimates giredestrant could generate $14.5 billion in peak sales. Roche shares fall 0.4%.  Dow Jones NewswiresJuly 15, 2026 03:33 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4211":"区域性银行","RHHBY":"罗氏控股","HRTS":"Tema Heart & Health ETF","CANC":"TEMA ONCOLOGY ETF","03165":"华夏欧优股对冲","ISBC":"投资者银行"},"translate_title":"罗氏投资者可能会对业绩不屑一顾，专注于新型抗癌药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRTS":0.6,"03165":0.6,"ISBC":1.5,"CANC":0.6,"RHHBY":0.9},"content_text":"0733 GMT - Roche Holding's first-half results should contain few surprises and investors might focus instead on the upcoming launch of a new breast-cancer drug, Citi analysts say in a note. The Swiss drugmaker is expected to report steady growth in first-half sales and core earnings when it releases results next week, the analysts say. Citi estimates Roche's half-year core earnings per share at 10.36 Swiss francs on sales of 30.3 billion francs. With no binary late-stage study results left this year, investors will increasingly focus on the huge opportunity for Roche's giredestrant treatment for breast cancer, the analysts say. U.S. drug regulators are due to decide on its approval by the end of November and Citi estimates giredestrant could generate $14.5 billion in peak sales. Roche shares fall 0.4%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 15, 2026 03:33 ET (07:33 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651031430","isCrawlerRequest":true}